With the acquisition of ICCR-Roßdorf GmbH (ICCR-Roßdorf), GBA Group, a German healthcare services company, has expanded its toxicology service offerings to include specialized genotoxicity testing for pharmaceuticals and medical devices. The deal was announced on September 20, 2023, with the transaction closing on the same day.
Transaction overview
GBA Group acquired ICCR-Roßdorf, a German toxicology services provider established in 1986. ICCR-Roßdorf operates from its headquarters near Darmstadt and employs nearly 100 staff members. The company specializes in assessing the genotoxic potential of pharmaceuticals, agrochemicals, cosmetics, and chemicals through detailed investigations. Additionally, it offers modified protocols for evaluating extract effects on medical devices.
Deal structure and financing
The transaction details, including the deal value and equity/debt split, were not disclosed. GBA Group engaged Quadriga Capital as its financial advisor for this acquisition, though sell-side advisors remain undisclosed. No specific leverage metrics or lock-up terms were mentioned in public announcements. The possibility of an IPO optionality post-acquisition was also not addressed.
Strategic context
GBA Group's rationale behind acquiring ICCR-Roßdorf is to enhance its portfolio of toxicology services and strengthen its position as a leading provider of life science services internationally. By integrating ICCR-Roßdorf’s specialized genotoxicity testing capabilities, GBA Group aims to better serve customers in the chemical, medical device, and pharmaceutical industries. ICCR-Roßdorf’s expertise complements GBA Group's existing service offerings, enabling it to offer a more comprehensive range of toxicology assessments.
Regulatory path
The acquisition did not require review by any regulatory bodies, as the deal value was undisclosed and likely below thresholds triggering mandatory filings in Germany or other relevant jurisdictions. Given the nature of the transaction within Germany’s healthcare sector, no significant antitrust concerns were raised, and thus no remedies or divestiture requirements were necessary.
This strategic move by GBA Group underscores its ambition to grow its toxicology services portfolio through targeted acquisitions, positioning itself as a robust player in the international life science service market.